Advanced Enzyme Technologies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong full-year results with consolidated revenue growing 17% to ₹7,457.57 million from ₹6,369.10 million. Profit after tax surged 29.6% to ₹1,736.08 million from ₹1,339.74 million, driven by improved operational efficiency. Basic EPS increased to ₹15.08 from ₹11.72. The Board recommended a final dividend of ₹1.35 per share (67.5% payout) for FY26, subject to shareholder approval. Notably, the Board deferred declaring an interim dividend, citing plans to preserve capital for potential strategic acquisitions or corporate actions. The company also allotted 49,350 equity shares under its ESOP scheme 2022, increasing paid-up capital to ₹22,39,52,300. Statutory auditors MSKA & Associates gave an unmodified (clean) opinion on the financial statements.
The 30% PAT growth and EBITDA margin expansion signal operational strength. However, the deferred interim dividend and capital preservation strategy suggest the company may be eyeing acquisitions, which could create future value but delays immediate shareholder returns.